Novartis Investigative Site

Chuo-ku, Tokyo 1040045

7 studies enrolling now · 67 studies all time

What they study most

Advanced CCNE1-amplified Solid Tumors, Advanced Endometrial Cancer, Advanced Gastric Cancer, Advanced HR+/HER2- Breast Cancer, Advanced NET of GI Origin, Advanced NET of Lung Origin, Advanced Neuroendocrine Tumors of Pancreatic Origin, Advanced Solid and Hematological TP53wt Tumors, Anal Cancer, Ankylosing Spondylitis, Asthma, Breast Cancer

Studies at this site

• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
• An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. — Recruiting now
• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC — Recruiting now
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors — Recruiting now
• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
• Dabrafenib and/or Trametinib Rollover Study — Recruiting now
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Recruiting now
• CAR-T Long Term Follow Up (LTFU) Study — Recruiting now
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) — Running, not enrolling
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients — Running, not enrolling
• A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Running, not enrolling
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects — Stopped early
• Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Running, not enrolling
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — Completed
• Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome — Completed
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation — Running, not enrolling
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. — Running, not enrolling
• An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. — Completed
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers — Running, not enrolling
• Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer — Stopped early
• Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome — Completed
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies — Stopped early
• A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab — Stopped early
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. — Completed
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. — Stopped early
• FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression — Completed
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
• Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies — Stopped early
• Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma — Stopped early
• Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients — Completed
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
• Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy — Stopped early
• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) — Completed
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations — Stopped early
• Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma — Stopped early
• Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas — Stopped early
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
• Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) — Completed
• Dose Finding Study for QAW039 in Asthma — Completed
• PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer — Completed
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Completed